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Effect of metformin on body mass index in adolescent fem ales
with polycystic ovary syndrome
Alissa Briggs, PhD, Mandakini Sadhir, MD,
Maya Todd, and Hatim Omar•, MD

Division o f Adolescent Medicine and Young Parent
Programs, Kentucky Clinic, Department o f Pediatrics,
Kentucky Children's Hospital, University of Kentucky
College o f Medicine, Lexington, Kentucky,USA

Abstract
Polycystic ovary syndrome (PCOS) is often associated with
obesity, insulin resistance, irregular menstrual periods and
pelvic pain. Treatment involves hormonal methods for
regulation of menstrual cycle, lifestyle changes and
metformin for improving insulin resistance and weight. The
aim of our study was to compare changes in body mass
index (BMI) of adolescent female with PCOS treated with
metformin as compared to lifestyle modification only.
Participants: Adolescent and young adult females aged I 025 years diagnosed with PCOS seen for at least two visits
for at least one year on the same treatment. Based on
treatment plan, participants were categorized as metformin
(metformin + lifestyle changes; metformin + oral
contraceptive pills+ lifestyle changes) versus control group
(oral contraceptive pills + lifestyle changes; lifestyle
changes only). Results: Of the 464 charts reviewed, 134
participants met the inclusion criteria. The average time

period between the initial and follow up visit on same
treatment plan was two years (Range 1-8 years).The
average age of patients at baseline (initial visit) and follow
up was 15.3 and 17.7 years, respectively. The majority of
participants were overweight or obese at baseline and
follow up. There was not a significant difference between
the metformin and control group in the number of patients
who stayed in the same BMI category, went up in a BMI
category, or went dowo in a BMI category from baseline to
follow up (x" - 1.93, p - 0.38). Conclusion: Treatment
with metformin did not relate to changes in BMI
classification over a year or more.
Keywords: Obesity, PCOS, metformin, adolescent female,

BMI

Introduction
• Correspondence: Hatim A Omar, MD, FAAP, Professor of
Pediatrics and Obstetrics/Gynecology, Children's Miracle
Network Chair, Chief, Division of Adolescent Medicine
and Young Parents Program (IA12), Kentucky Children's
Hospital, UK Healthcare, Department of Pediatrics,
University of Kentucky College of Medicine, Lexington,
KY 40536, United States. E-mail: haomar2@uky.edu

Polycystic ovary syndrome (PCOS) is a complex
endocrine disorder among reproductive age women. It
is characterized b y chronic anovulation leading to
menstrual irregularities, pelvic pain and hy p erandrogenism manifested as hirsutism, acne, and
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alopecia along with elevated serum androgen levels
(1 ). PCOS is diagnosed using various criteria
commonly known as NIH, Rotterdam and Androgen
Excess society. In 1990, the National Institutes o f
Health (NIH) held a conference on PCOS to create
both a working definition of the disorder and
diagnostic criteria. The outcome of this conference,
the NIH Criteria, served as a standard for researchers
and clinicians for more than a decade. In 2003, a
consensus workshop in Rotterdam in the Netherlands
develo p ed new diagnostic criteria, the Rotterdam
Criteria. The Androgen Excess (AE) and PCOS
Society proposed the AE-PCOS Criteria in 2006. It
has an estimated prevalence o f 5-10% among adult
females (2, 3). Limited data exists about incidence
and prevalence of PCOS in adolescent females and
diagnosis continues to be challenging (4-6). Higher
incidence o f PCOS is seen with obesity, history of
premature adrenarche, and family history o f PCOS (79).
The exact etiology of PCOS remains unknown,
but there is evidence that supports genetic and
lifestyle factors in the development of PCOS. Studies
have suggested the role of insulin resistance for the
development of ovarian and pituitary dysfunction (I 0,
11 ). In PCOS, there is relative increase in LH
pulsatile secretion from the pituitary gland leading to
altered high LH to FSH ratio (1.5-2:1). As a result,
there is increase in ovarian androgen biosynthesis. In
addition, high insulin levels stimulate ovarian
androgen production and inhibit hepatic production of
sex hormone binding globulin. Further, decrease in
pituitary FSH secretion leads to less aromatization of
androgens to estradiol which affects follicular
development and ovulation (12).
In adolescent females, PCOS is often associated
with obesity with increased risk of metabolic
disturbances, including impaired glucose tolerance
and dyslipidemia. Treatment of PCOS in adolescent
female involves a multidisciplina r y approach to
decrease future risk of endometrial cancer, diabetes
mellitus and cardiovascular disease (13). It involves
menstrual regulation, addressing features of
hyperandrogenism such as hirsutism, acne, and
weight management to improve insulin resistance.
Treatment of obesity has been associated with
improvement in menstrual irregularity and insulin
resistance (14).

Menstrual regulation is often done using oral
contraceptive pills, which also helps to improve sex
hormone binding globulin and free testosterone. In
addition, studies have found metforrnin to be
beneficial for improving follicular develo pment and
insulin resistance (14). Recent meta-analysis showed
that lifestyle changes and metformin were associated
with lower BMI and subcutaneous adipose tissue with
improved menstruation in women with PCOS as
compared with lifestyle changes only (15).
Randomized control trials comparing metforrnin with
oral contraceptive pills showed significant
improvement in BMI over 6 month period (16, 17).
Currently, there is limited data on long term changes
in BMI in adolescent females with PCOS on
treatment with metformin. In our study, it was
hypothesized that adolescent female treated with
metforrnin would have a decrease in BMI as
compared to those on lifestyle modifications only
when followed for at least a year.

Methods
A retrospective chart review of adolescent females
(12-21 years) who were seen, diagnosed and treated
for PCOS in the Adolescent Medicine clinic was
conducted. The study was approved by the
Institutional Review Board. The charts were pulled
using the billing diagnosis of PCOS, obesity, and
insulin resistance. Upon chart review, participants
who met the NIH criteria of PCOS (oligo-ovulation,
clinical or biochemical hy p er-androgenemia and
exclusion of other mimicking disorders) and followed
up in clinic for at least one year on the same treatment
plan (metforrnin only, metforrnin with oral
contraceptives, oral contraceptives only, and lifestyle
modifications only) were included. In order to be
included in the study, charts needed to have the
following data at an initial visit and follow up visit on
the same treatment plan over at least a year: age,
weight, and height. Charts with treatment plans such
as Depo-Provera, implanon, intrauterine device,
vaginal ring, and patch were excluded as they were
not the focus o f the present study. Using these criteria,
134 out of 464 charts reviewed were included in the
study. Participants were then categorized into two
groups based on treatment plan: metforrnin and
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control. Participants who had been treated with
metfomrin only or metfomrin and oral contraceptive
pills were categorized as the metfomrin group.
Participants who were treated with oral contraceptive
pills only or lifestyle modifications without
medication were included in control group.
Nutritional counseling and lifestyle modification were
part of management in all participants. Participants
were further classified as healthy (18.5-24.9),
overweight (25-29.5), obese (2:30 kg/m2) and
extremely obese (2:35 kg/m2) using CDC guidelines
for Body Mass Index (BMI) in the treatment group.
Descriptive analysis was done to identify those who
increased, decreased or experienced no change in
BM! from baseline to follow up. Chi-square analyses
were performed to detemrine i f groups differed in
whether or not they increased, decreased, or stayed
the same in terms ofBMI category.

Results
The average time period between initial visit and
follow up on same treatment plan was 2 years
(range = 1-8 years). The average age o f patients at
baseline was 15 .34 years and the average age at
follow up was 17.7 years. While majority o f patients
were White (n = 82, 61.2%), others were identified as
Black (n = 45, 33.6%), Hispanic (n = 3, 2.2%), Asian
(n = 2, 1.5%), and two or more races (n = 2, 1.5%).
About half o f the patients were on metfomrin and oral
contraceptive pills (n = 73, 54.5%). A third o f patients
(n = 44) were on oral contraceptive pills only. Only a
few patients were on metfomrin only (n = 6, 4.5%).
Eleven patients were not on any medication
(n = 8.2%). When grouped in two categories, 41 %
(n = 55) patients were in the metfomrin group and
59% (n = 79) in the control group.

Table 1. Distribution of participants in Metformin and Control group and their BMI classification at baseline
and follow up

Study Group
No metformin/
Control group
(n = 55)
Metformin
group
(n = 79)

Lifestyle modification
(n = 11), n (%)
Birth Control
(n -44), n (%)
Metformin + Birth
Control (n = 73), n (%)
Metformin
(n - 6 ) , n (%)

Baseline

Follow-up
Baseline

Follow-up
Baseline

Follow-up

Baseline

Follow-up

Healthy Weight
0(0%)
I (9%)
10 (23%)
II (25%)
6(8%)
5 (7%)
0(0%)
0(0%)

Overweight
4 (36%)
I (9%)
15 (34%)
7 (16%)
39 (53%)
5 (7%)
0(0%)
I (17%)

Obese
6 (55%)
5 (46%)
17 (39%)
22 (50%)
10 (14%)
34 (46%)
5 (83%)
3 (50%)

Extremely Obese
I (9%)
4 (36%)
2(4%)
4 (9%)
18 (25%)
29 (40%)
I (17%)
2 (33%)

Table 2. The percent o f patients in each treatment group stayed in the same BMI classification or change
BMI classifications

No Metformin (n = 55), n (%)
Metformin (n = 79), n (%)

No Change
33 (60%)
56 (71%)

At baseline and follow up, the majority o f patients
were overweight or obese (see Table I). No patients
were underweight. The majority o f patients
experienced no change in BM! classification and few
fell into a lower BMI classification at follow-up (see
Table 2). There was not a siguificant difference
between groups in the number o f patients who stayed
in the same BMI category, went up in a BM!
category, or went down in a BMI category from
baseline to follow-up (X2 = 1.93, p = 0.38).

Increase
17(31%)
19 (24%)

Decrease
5 (9%)
4(5%)

Discussion
Our study is among the first few to investigate
changes in body mass index in adolescent females
with PCOS on metformin versus not on metfomrin
over an average duration o f two years. In our study
sample, adolescent females on metformin continued
to be overweight or obese. This is in contrast to
previous studies which had shown improvement in
BM! when treated with metfomrin over a 6 month
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period (16, 17). In those studies, the investigators
ensured compliaoce aod adhereoce to a treatment
regimeo through direct contact aod frequeot
reminders. Adhereoce to treatmeot is ofteo a
challeoge in adolesceoce. In our study sample, there
was no significaot chaoge in BMI betweeo metformin
aod control group. 1bis could be attributed to
noncompliaoce to the treatmeot regimeo over a long
period o f time. Or, it could be that the initial weight
loss observed in other studies is challeoged by
lifestyle choices over the long term. Another
limitation o f the study is its retrospective nature.
Giveo the retrospective nature o f the data, there were
several appointmeots where data was missing aod
treatmeot plaos chaoged. Ideally, baseline aod follow
up would be over the same amount o f time for each
patient. However, follow up appointments happened
at different intervals aod sometimes did not have all
the necessary data to allow for a comparison (e.g.,
height was ofteo missing). Thus, i f a follow up
occurred at a year aod data were missing, a later
follow up appoint that included all data needed to be
selected. Some patients did not return for follow up
appoints until over a year later. Furthermore, some
patients' treatment plaos chaoged too frequently to
allow for a baseline aod follow up comparison.
Prospective studies could be designed to study effect
o f metformin on weight loss over a longer, consistent
period with emphasis on adherence.
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